Shenzhen Chipscreen Biosciences Past Earnings Performance
Past criteria checks 0/6
Shenzhen Chipscreen Biosciences has been growing earnings at an average annual rate of 4.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 23.8% per year.
Key information
4.4%
Earnings growth rate
3.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 23.8% |
| Return on equity | -4.3% |
| Net Margin | -10.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shenzhen Chipscreen Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 656 | -70 | 384 | 207 |
| 30 Jun 24 | 584 | -108 | 364 | 210 |
| 31 Mar 24 | 548 | 103 | 366 | 270 |
| 31 Dec 23 | 524 | 89 | 369 | 270 |
| 30 Sep 23 | 543 | 168 | 357 | 246 |
| 30 Jun 23 | 556 | 192 | 361 | 250 |
| 31 Mar 23 | 532 | -11 | 327 | 180 |
| 31 Dec 22 | 530 | 17 | 317 | 164 |
| 30 Sep 22 | 490 | 4 | 307 | 167 |
| 30 Jun 22 | 463 | 10 | 299 | 148 |
| 31 Mar 22 | 460 | 26 | 293 | 141 |
| 31 Dec 21 | 430 | 22 | 289 | 130 |
| 30 Sep 21 | 360 | -32 | 271 | 126 |
| 30 Jun 21 | 342 | -5 | 236 | 115 |
| 31 Mar 21 | 312 | 19 | 202 | 107 |
| 31 Dec 20 | 269 | 31 | 164 | 92 |
| 30 Sep 20 | 231 | 37 | 149 | 69 |
| 30 Jun 20 | 202 | 31 | 131 | 65 |
| 31 Mar 20 | 181 | 23 | 115 | 54 |
| 31 Dec 19 | 174 | 19 | 107 | 51 |
| 30 Sep 19 | 181 | 37 | 89 | 52 |
| 30 Jun 19 | 157 | 31 | 84 | 45 |
| 31 Mar 19 | 142 | 28 | 79 | 42 |
| 31 Dec 18 | 148 | 31 | 80 | 43 |
| 31 Dec 17 | 111 | 24 | 54 | 38 |
| 31 Dec 16 | 85 | 5 | 48 | 32 |
Quality Earnings: 688321 is currently unprofitable.
Growing Profit Margin: 688321 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688321 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare 688321's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688321 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 688321 has a negative Return on Equity (-4.28%), as it is currently unprofitable.